Why We Fail at Cancer Clinical Trials So Often: An Anesthesiologist’s Perspective

Editorial| March 2024 Why We Fail at Cancer Clinical Trials So Often: An Anesthesiologist's Perspective Jian Hu, Ph.D. Jian Hu, Ph.D. 1Department of Cancer Biology, Cancer Neuroscience Program, University of Texas M.D. Anderson Cancer Center, Houston, Texas; Cancer Biology Program and Neuroscience Program, M.D. Anderson Cancer Center, University of Texas Health Graduate School of Biomedical Sciences, Houston, Texas. https://orcid.org/0000-0001-9760-2013 Search for other works by this author on: This Site PubMed Google Scholar Author and Article Information This editorial accompanies the article on p. 361. Accepted for publication December 4, 2023. Address correspondence to Dr. Hu: Anesthesiology March 2024, Vol. 140, 349–351. https://doi.org/10.1097/ALN.0000000000004859 Connected Content Article: Lost in Translation: Failure of Preclinical Studies to Accurately Predict the Effect of Regional Analgesia on Cancer Recurrence Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn Email Cite Icon Cite Get Permissions Search Site Citation Jian Hu; Why We Fail at Cancer Clinical Trials So Often: An Anesthesiologist's Perspective. Anesthesiology 2024; 140:349–351 doi: https://doi.org/10.1097/ALN.0000000000004859 Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest filter your search All ContentAll PublicationsAnesthesiology Search Advanced Search Topics: cancer According to the National Cancer Institute (Bethesda, Maryland), an estimated 1.9 million new cancer cases and 0.6 million cancer-related deaths are projected in the United States in 2023. Clinical trials represent a critical and final stage in the process of introducing a new drug or medical device to human patients. However, the overall success rate of clinical trials in the modern era is notably low, with an estimated success rate for bringing a new cancer treatment from initial development to U.S. Food and Drug Administration (Silver Spring, Maryland) approval standing at only 3 to 5%.1 Various factors can contribute to the failure of a clinical trial, and these factors may vary depending on its phase. Inadequately validated targets, safety concerns, challenges in patient recruitment and retention, and suboptimal study design are among the issues that can affect the success of clinical trials. In a review authored by two anesthesiologists,... You do not currently have access to this content.